Replimune

Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released.
Type
Private
HQ
Milton, GB
Founded
2015
Replimune was founded in 2015 and is headquartered in Milton, GB

Replimune Locations

Milton, GB
Woburn, US

Replimune Metrics

Replimune Summary

Founding Date

2015

Total Funding

$30 M

Latest funding size

$30 M

Time since last funding

about 1 year

Investors

Replimune's latest funding round of $30 M was in September 2015. In total, Replimune has raised $30 M.

Replimune Company Life